It's a high risk business, says Marijn Dekkers, Bayer CEO, discussing price controls and the huge expense associated with innovating and developing new drugs.» Read More
The jobs crisis has brought an unwelcome discovery for many unemployed Americans: job openings in their old fields exist. Yet they no longer qualify for them.
Shares in European airline and travel stocks fell heavily on Monday as ash from an Icelandic volcano looked set to bring much of Europe to a standstill for a 5th straight day.
I didn’t inhale. It’s the truth. I swear. I have never ever taken a toke on a joint or even a cigarette. Growing up, my parents were both smokers and I think I developed such a distaste for the constant cloud that it just never held any appeal for me.
At the risk of getting more emails from conspiracy-theorist readers who think I report too much negative news about Pfizer, here comes another setback for the world's biggest drug company.
On the Pfizer earnings conference call this morning Chairman and CEO Jeff Kindler kicked things off by calling this a "time of great uncertainty in the world economy and capital markets and significant challenges in our industry."
More than ten years after Pfizer brought Viagra to market and brought erectile dysfunction out of the closet a new survey says a lot of men are still too embarrassed to talk about impotence with their doctor.
A study claims "the time has come" for researchers to study ED drugs as preventive medicine for the heart.
If you watch "Project Runway," the future of judge Nina Garcia has been up in the air since she left Elle. Now we know the sort of career opportunities she's exploring. Not developing a new clothing line, or another magazine job, or designing shoes.
I like to think I have a nose for news. And, some might say, too much of a penchant for puns and alliteration. Impotence drug profits won't be going up big pharma's nose. The tiny New Jersey-based biotech company Palatin Technologies says it's giving up on its experimental nasal spray for erectile dysfunction.
Stocks ticked higher Monday amid merger buzz but index gains were modest as the market awaits the Federal Reserve's rate decision later this week.
Stocks retreated after an early pop Monday as the early market buzz was all about deals and deal makers.
Last night while on the elliptical and watching "NBC Nightly News," one spot amid the wall-to-wall commercials for drugs caught my attention. It looks like after 10 years since the first erectile dysfunction pill came on the market--Pfizer's Viagra celebrated a decade since winning FDA approval last week--the makers of Levitra are trying a new marketing tack.
When the economy rebounds, where's your portfolio going to be? UBS says that's a question to answer right now. The bank released what it calls its "'New' Nifty Fifty," a list of 50 companies from around the world that can use today's troubling market conditions to position themselves to thrive when the economy rebounds. (PART 2)
For a Monday before the Thanksgiving holiday, this is turning into an extremely busy day on the biotech beat. Two of the stories actually broke on Sunday: Celgene buying Pharmion for nearly $3 billion and Genentech announcing a breakthrough in brain cancer. Then, before the opening bell this morning Onyx Pharmaceuticals and Bayer won the expected Food and Drug Administration approval of their drug Nexavar for liver cancer.
Drug maker Bayer said Tuesday that it will delist its shares from the New York Stock Exchange this week, a move the company said would save it $21.2 million per year.
Stocks closed broadly lower at the end of a light-volume trading session as continued weakness in financial stocks brought down the major indexes. The Dow fell 56 points, closing near the lows of the trading session, while the S&P 500 and Nasdaq Composite ended with respective losses of 0.9% and 0.6%, respectively.
Onyx Pharamaceuticals shares rose sharply after its partner Bayer said results of a Phase 3 study showed that Nexavar significantly extended overall survival in patients with liver cancer by 44%.
Stocks recovered from earlier losses to close near the unchanged mark as investors took positions ahead of tomorrow's Fed meeting. "Investors are basically still cautious despite this big run and although we're very overbought, I think the fact that we could get this overbought is bullish in itself," said Bruce Bittles, chief investment strategist at Robert W. Baird.
Onyx Pharmaceuticals is up big for the second day in a row. The stock nearly doubled yesterday on astronomical volume of 56,000,000 shares and today as I write this it's up almost 8% with more than 18,000,000 shares changing hands. So, what's up besides the stock?